

26 **Abstract**

27

28 *Objective:* Recent mutations in SARS-CoV-2 raised concerns about diminishing vaccine
29 effectiveness against COVID-19 caused by particular variants. Even with a high initial efficacy,
30 if a vaccine's efficacy drops significantly against variants, or if it cannot be distributed quickly, it
31 is uncertain whether the vaccine can provide better health outcomes than other vaccines. Hence,
32 we evaluated the trade-offs between *speed of distribution* vs. *efficacy* of multiple vaccines when
33 variants emerge.

34

35 *Methods:* We utilized a Susceptible-Infected-Recovered-Deceased (SIR-D) model to simulate the
36 impact of immunization using different vaccines with varying efficacies and assessed the level of
37 *infection attack rate* (IAR) under different speeds of vaccine distribution.

38

39 *Results:* We found that a vaccine with low efficacy both before and after variants may
40 outperform a vaccine with high efficacy if the former can be distributed more quickly.
41 Particularly, a vaccine with 65% and 60% efficacy before and after the variants, respectively, can
42 outperform a vaccine with 95% and 90% efficacy, if its distribution is 46% to 48% faster (with
43 the selected study parameters).

44

45 *Conclusions:* Our results show that speed is a key factor to a successful immunization strategy to
46 control the COVID-19 pandemic even when the emerging variants may reduce the efficacy of a
47 vaccine.

48

49 **Keywords:** vaccination; disease modeling; COVID-19; vaccine efficacy; distribution speed

50 **Preference for colors** in Table 2, Figure 1, Figure 2, Figure 3: Online Only

51 **Word Count**

52 Word Count (Abstract): 200 Word Count (Text): 3404

53 Figure/Table Count: 5 References Count: 36

54

55 **Introduction**

56 Since the initial reports of a cluster of pneumonia cases of unidentified origin in Wuhan,
57 China, in December 2019, more than 133 million people around the world have been infected
58 with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite the
59 development of effective vaccines in unprecedented speed, concerns have been raised on the
60 potential reduction in efficacy of these vaccines against the new SARS-CoV-2 variants due to
61 possible evasion from antibody recognition [1]. Most of the vaccines were developed and tested
62 before the new variants of SARS-CoV-2 emerged. In order to reach herd immunity, effective
63 implementation of a vaccine with sufficient efficacy against the circulating dominant variants is
64 essential. Subsequently, it becomes a trivial decision for policymakers and governments to favor
65 a vaccine with high efficacy for distribution. However, if the vaccine cannot be dispensed
66 quickly and/or if its efficacy drops significantly against the emerging variants compared to other
67 vaccines, the question of which vaccine should be favored is no longer trivial. Hence, the goal of
68 this study is to understand the tradeoffs between the speed of distribution vs. the change in the
69 efficacy levels of SARS-CoV-2 vaccines before and after the emergence of variants, which we
70 refer to as "initial efficacy" and "final efficacy", respectively, hereafter.

71 As of March 2021, twelve vaccines have received authorizations for emergency use around
72 the world [2]. Pfizer-BioNTech's mRNA vaccine, which was the first authorized vaccine in the
73 United States, has an initial efficacy of 95% and needs to be stored at about minus 70 degrees
74 Celsius [3, 4]. Moderna's mRNA vaccine has an initial efficacy of 94.5% and needs to be stored
75 at about minus 25 degrees Celsius [5]. Both mRNA vaccines require two doses with three to four
76 weeks apart application. Johnson & Johnson's adenovirus-vectored vaccine has an average initial
77 efficacy of 66.3%, requires only a single dose, and needs to be stored at about 2-8 degrees

78 Celsius [6]. Even though there are multiple authorized vaccines, their distribution and
79 administration have been slow. By the end of 2020, only 2.8 million people received the *first*
80 dose of COVID-19 mRNA vaccines in the United States [7]. Moreover, the Centers for Disease
81 Control and Prevention (CDC) reports that only about 10% of the population have been fully
82 vaccinated as of March 11, 2021 [8].

83 In addition to distributional challenges, reduction in efficacy of vaccines against emerging
84 variants has raised concerns. As of March 2021, three main SARS-CoV-2 variants have been
85 identified. The B.1.1.7 variant, first identified in the United Kingdom in September 2020, caused
86 more than 28% of the infected cases in the United Kingdom in late December 2020, spread 56%
87 more quickly than other variants, and has become dominant in the United States [9, 10]. Another
88 variant B.1.351, first identified in South Africa in December 2020, has become dominant,
89 making up to 90% of infections, in South Africa and has been detected in several countries. The
90 last variant P.1 has been identified in Japan from travelers from Brazil in January 2021. In
91 response, scientists and vaccine manufactures have been testing the efficacy of the vaccines
92 against the variants and report that the B.1.1.7 variant is neutralized by most of the vaccines,
93 supporting the retention of the efficacy [11]. However, in vitro studies show that the vaccines'
94 neutralization of B.1.351 variant is significantly lower than that of other variants [12, 13]. In
95 particular, the distribution of AstraZeneca's adenovirus-vectored vaccine in South Africa has
96 been halted due to its low efficacy against the B.1.351 variant. Similarly, Novavax states that its
97 protein-based vaccine is 85.6% effective against the B.1.1.7 variant but 60% effective against the
98 B.1.351 variant [14].

99 In this paper, we study the trade-offs between vaccines' efficacy levels, which are subject to
100 reduction due to emerging variants and speed of vaccine distribution by using a modified

101 Susceptible-Infected-Recovered-Deceased (SIR-D) model and simulating the *infection attack*
102 *rate* (IAR) under different times that the virus variants emerge. Throughout this paper, we refer
103 to vaccine distribution as the entire distribution process of a vaccine including delivery to the
104 dispensation sites and administration to the population. The results of this study are aimed to
105 guide decision-makers in vaccine ordering during a pandemic when there are multiple types of
106 vaccines, facing reduced efficacies as variants emerge.

107 **Methods**

108 To compare different vaccine types, we categorized the level of the vaccine efficacy into
109 three ranges: “H” (High) if 90% or above, M (Moderate) if higher than 70% and lower than 90%,
110 and L (Low) if lower than 70%. We assumed that the final efficacy was always lower than the
111 initial efficacy. In our main simulation, we considered three initial efficacy levels ($H_i = 95\%$,
112 $M_i = 75\%$, and $L_i = 65\%$) and three final efficacy levels ($H_f = 90\%$, $M_f = 70\%$, and $L_f = 60\%$).
113 Consequently, we obtained six types of vaccines, defined by a particular initial and final efficacy,
114 as summarized in Table 1. These modeling choices were motivated by recent studies on vaccine
115 efficacy against variants. The recently updated analysis of Pfizer-BioNTech’s phase 3 clinical
116 trials showed that their vaccine is effective against the B.1.351 variant [15]. The clinical trials of
117 Johnson & Johnson’s adenovirus-vectored vaccine showed an efficacy of 57% in South Africa,
118 where the B.1.351 variant is dominant [16]. Hence, in our model, vaccine- H_iH_f or vaccine- H_iM_f
119 may represent Pfizer-BioNTech’s mRNA vaccine and vaccine- L_iL_f may represent Johnson &
120 Johnson’s adenovirus-vectored vaccine.

121

122 Table 1: Vaccine Efficacy

Vaccine Type	Initial Efficacy	Final Efficacy
H_iH_f	95%	90%
H_iM_f	95%	70%
H_iL_f	95%	60%
M_iM_f	75%	70%
M_iL_f	75%	60%
L_iL_f	65%	60%

123 Even though all authorized COVID-19 vaccines, except for Johnson & Johnson’s adenovirus-
124 vectored vaccine, require two doses, we assumed in our simulations that all vaccines require a
125 single dose and an individual who receives an *effective* vaccine becomes immunized immediately.
126 In each simulation, only a single type of vaccine was administered, and the daily vaccine
127 distribution capacity was kept constant at $\lambda \cdot K$, where K represents base capacity and λ is a
128 multiplier. We fixed the base capacity, K , at 500,000, motivated from the average number of
129 vaccine recipients in each day in the United States from December 14, 2020 to March 2, 2021,
130 and we set a range of 1.0 to 3.0 with increments of 0.2 for the capacity multiplier λ to represent
131 the speed of distribution in our simulations [8].

132 In our study, we utilized a modified SIR-D (Susceptible-Infectious-Recovered-Deceased)
133 compartmental model, which is a simplified mathematical model of infectious diseases. In this
134 model, individuals are moving among compartments, and transitions between compartments are
135 governed by ordinary differential equations given epidemiological and vaccine parameters. We
136 implemented seven compartments: Susceptible, Immunized, Vaccinated-susceptible,
137 Symptomatic-infectious, Asymptomatic-infectious, Recovered, and Deceased. When *Susceptible*

138 population receives vaccines, they enter either the *Immunized* compartment if the vaccine is
139 effective, or the *Vaccinated-susceptible* compartment, otherwise. Both Susceptible and
140 Vaccinated-susceptible populations enter either the *Symptomatic-infectious* or *Asymptomatic-*
141 *infectious* compartment, depending on whether they show symptoms or not, once they make
142 infectious contacts with the infected population. Symptomatic-infectious population moves to
143 either the *Recovered* or *Deceased* compartment. Asymptomatic-infectious population, on the
144 other hand, moves only to the Recovered compartment.

145 We chose the epidemiological parameter values that govern the transitions in the
146 compartment model based on the estimated SARS-CoV-2 characteristics in various studies. You
147 et al. (2020) and Byrne et al. (2020) reported that the infectious period of a symptomatic patient
148 and an asymptomatic patient was around 14 days and 8 days, respectively [17, 18]. Therefore,
149 we set the recovery rates of symptomatic patients (γ_s) and asymptomatic patients (γ_a) at 1/14 and
150 1/8, respectively. In addition, the CDC has developed COVID-19 Pandemic Planning Scenarios
151 and provided parameter values to use in a mathematical model [19]. Accordingly, we assumed
152 that 60% of the susceptible population who make infectious contacts become symptomatic. In
153 addition, we used 2.3 for the reproduction number, which is often employed by epidemiologists
154 to represent the severity of a disease. Even though the CDC's planning scenarios, lastly updated
155 in September 2020, specify a reproduction number of 2.5 as the best planning estimate, we
156 expect a lower reproduction number due to an increase in mask use and the implementation of
157 various non-pharmaceutical interventions [20]. Basu (2020) reported that the symptomatic
158 infection fatality rate (IFR-S) of COVID-19, the proportion of deaths among symptomatic
159 infected individuals, was estimated to be 1.3% [21]. Given the reproduction number of 2.3 and
160 the IFR-S, we set the symptomatic-transmission rate (β_s) to be 0.22031 and the death rate (μ) to

161 be 0.0032. We assumed that the asymptomatic-transmission rate (β_a) was 75% of the
162 symptomatic-transmission rate [22]. We used R-software to run the simulations with a
163 population size of 330 million (approximate population of the United States). Since our main
164 goal is to analyze the trade-offs between distribution speed and vaccine's efficacy under variants,
165 we started the simulation only after when the vaccine becomes available and initialized it such
166 that around 28% of the population had already been infected. Thus, we set 2.90% of the
167 population as symptomatic-infected, 1.15% as asymptomatic-infected, 24.44% as recovered, and
168 0.14% as deceased. These estimates were motivated by the *confirmed* cumulative cases and
169 deaths as of December 14, 2020, the first day of vaccine distribution in the United States [23].
170 However, we multiplied the number of *confirmed* infections by six and increased the number of
171 *confirmed* deaths by 35% in line with the findings of Wu et al. (2020) and Noh and Danuser
172 (2021), who reported that the number of COVID-19 confirmed cumulative cases was
173 underestimated, and Kung et al. (2020), who showed the same for confirmed deaths [24-26]. The
174 initial values in other compartments were estimated using the epidemiological parameters
175 defined previously. We ran the simulation on a one-year planning horizon under different
176 *mutation times* (i.e., the time at which the emerging variants cause a decrease in a vaccine's
177 efficacy) within the range of day 5 to day 40 with a discrete step size of 5 days, and different
178 *capacity multipliers* (λ) within the range of 1.0 to 3.0 with a discrete step size of 0.2 to capture
179 the vaccine distribution speed. We evaluated the impact of each vaccine type using IAR as the
180 main health outcome.

181 **Results**

182 We first ran our simulation without the presence of any vaccines, which gave an estimated
183 IAR of approximately 81% and IFR-S of 2%. The daily infection peak (i.e., the highest

184 percentage of the population who get newly infected on a single day) occurred on day 24, at
 185 which 1% of the population got newly infected.


186 Table 2 shows the estimated IAR under different capacity multipliers (λ) when the mutation
 187 times are day 5 and day 25. We report additional results with different mutation times in
 188 Supplemental Materials. When the mutation time is day 5, the level of IAR is between 60% and
 189 65% when the capacity multiplier is 3.0 (1.5M doses/day) and between 72% and 75% when the
 190 capacity multiplier is 1.0 (0.5M doses/day), depending on the selected vaccine type. When the
 191 mutation time is day 25, the level of IAR is smaller compared to when the mutation time is day 5,
 192 and the decrease in IAR due to the increase in capacity multiplier is larger.

193 *Table 2: Infection attack rate (%) under different capacity multipliers and vaccine types when*
 194 *mutation time is day 5 and day 25*


Capacity Multiplier (λ)	Mutation Time = Day 5						Mutation Time = Day 25					
	H_iH_f	H_iM_f	H_iL_f	M_iM_f	M_iL_f	L_iL_f	H_iH_f	H_iM_f	H_iL_f	M_iM_f	M_iL_f	L_iL_f
3.0	60.19	63.02	64.63	63.55	65.17	65.45	59.81	60.98	61.64	63.13	63.86	65.01
2.8	61.16	63.92	65.48	64.43	65.99	66.25	60.80	61.96	62.63	64.02	64.74	65.83
2.6	62.18	64.86	66.36	65.34	66.84	67.09	61.84	63.00	63.65	64.95	65.66	66.69
2.4	63.25	65.84	67.27	66.28	67.72	67.95	62.92	64.07	64.72	65.92	66.61	67.58
2.2	64.38	66.86	68.22	67.27	68.64	68.85	64.06	65.20	65.83	66.93	67.60	68.50
2.0	65.55	67.91	69.20	68.29	69.58	69.78	65.26	66.37	66.98	67.98	68.62	69.45
1.8	66.79	69.01	70.22	69.36	70.56	70.74	66.52	67.59	68.18	69.07	69.68	70.44
1.6	68.08	70.16	71.27	70.47	71.58	71.74	67.83	68.86	69.42	70.20	70.78	71.47
1.4	69.44	71.35	72.36	71.62	72.63	72.77	69.22	70.19	70.71	71.38	71.92	72.53
1.2	70.87	72.58	73.48	72.82	73.72	73.84	70.67	71.57	72.05	72.61	73.10	73.63
1.0	72.37	73.86	74.65	74.06	74.85	74.95	72.20	73.00	73.43	73.89	74.32	74.77

196 Figure 1 and Figure 2 present the contour plot and the two-dimensional plot of the IAR in
197 Table 2, respectively. Figure 1 shows that even vaccine- L_iL_f can achieve a lower IAR than
198 vaccine- H_iH_f if the capacity multiplier of vaccine- L_iL_f is high compared to that of vaccine- H_iH_f .
199 For instance, when the capacity multiplier of vaccine- H_iH_f is 1.0 and the mutation time is day 5,
200 72.3% of the population is infected. However, if the capacity multiplier of vaccine- L_iL_f is 1.48
201 (or higher), 72.2% (or less) of the population is infected. We present the minimum required
202 capacity multiplier of all vaccine types to achieve a lower IAR than vaccine- H_iH_f with the
203 capacity multiplier of 1.0 and 1.6 under different mutation times in Supplemental Materials.


204 Figure 3 compares the daily new infections from day 5 to day 50 with vaccine- H_iL_f vs.
205 vaccine- M_iM_f . In this figure, the mutation time is early (on day 5) and comes before the daily
206 infection peak, and thus, vaccine- M_iM_f results in a better IAR than vaccine- H_iL_f for all capacity
207 multipliers. Specifically, after the peak of daily new infections is reached for each vaccine, the
208 number of daily infections drops at a faster rate when vaccine- M_iM_f is administered. On the
209 other hand, when the mutation time comes after the daily infection peak (not shown in the figure),
210 vaccine- H_iL_f achieves a lower IAR than vaccine- M_iM_f for all capacity multipliers.



211 *Figure 1: Contour plot of infection attack rate under different capacity multipliers with different*
212 *vaccine types when mutation time is (a) day 5 and (b) day 25*



213 *Figure 2: Two-dimensional plot of infection attack rate under different capacity multipliers with*
214 *different vaccine types when mutation time is (a) day 5 and (b) day 25*



215
216 *Figure 3: Daily new infections from day 5 to day 50 with vaccine- and vaccine- when*
217 *the capacity multiplier (is 3 and the mutation time is day 5*

218 Discussion

219 In this study, we utilized a modified SIR-D model to simulate the trajectory of an infectious
220 disease under the intervention of different kinds of vaccines of which efficacies decrease against
221 the variants of the disease. We have demonstrated that the speed of the vaccine distribution is a
222 key factor to achieve low IAR levels, even though the vaccine may have high efficacy both
223 before and after the variants emerge. There have been many studies examining the trade-offs
224 between speed and efficacy [27, 28]. These studies emphasize the importance of wide
225 vaccination coverage, which is consistent with our study's findings. However, we considered a
226 decrease in efficacy of each vaccine type in the midst of the pandemic and reaffirmed the
227 importance of a rapid implementation of vaccination even under emerging variants.

228 Our study shows that a vaccine with low initial and final efficacy levels (vaccine-) can
229 achieve a lower IAR than a vaccine with high initial and final efficacy levels (vaccine-) if
230 the former can be distributed more quickly than the latter, regardless of the mutation time. For

231 instance, when the mutation time was day 25 and the capacity multiplier of vaccine- H_iH_f was
232 1.0 (0.5M doses/day), 72.2% of the population got infected. If the capacity multiplier of vaccine-
233 L_iL_f was 1.47 (0.73M doses/day or higher), 72.1% (or less) of the population was infected. Even
234 for vaccines with the same initial efficacy, such as vaccine- H_iH_f and vaccine- H_iL_f , this result
235 remained robust—vaccine- H_iL_f with a capacity multiplier of 1.18 (0.59M doses/day) or higher
236 achieved a lower IAR than vaccine- H_iH_f with a capacity multiplier of 1.0 (0.5M doses/day).

237 Since the start of the COVID-19 vaccination process, the speed of the vaccine distribution has
238 been slow due to numerous reasons, including limited and uncertain vaccine supply and various
239 logistics and storage challenges. Despite the continuing effort of increasing production capacities,
240 vaccine manufacturers, especially those who produce mRNA vaccines with new technology,
241 have been struggling to secure sufficient supply of vaccine ingredients, storage containers, and
242 more, due to the demand from billions of people around the world [29]. In addition, mRNA
243 vaccines need to be stored in ultra-cold freezers under specific expiration dates, although many
244 facilities lack or cannot afford such expensive ultra-cold freezers, leading to a limited number of
245 administration sites. Even the sites with the ability to administer these vaccine types need to
246 dispose the vaccines if they cannot be administered by the expiration date or stored at the
247 appropriate temperature [30, 31]. Unlike the mRNA vaccines, Johnson & Johnson's adenovirus-
248 vectored vaccine only requires a single dose and can be stored at the same temperature as the
249 seasonal flu vaccine. These characteristics prevent vaccine wastage, enable efficient production
250 and distribution using the existing vaccine supply chain, and facilitate a faster rate of vaccination
251 [32]. Hence, despite the lower efficacy, adenovirus-vectored vaccines that have the potential for
252 faster distribution may be more beneficial.

253 Increasing the doses distributed per day, i.e., the capacity multiplier (λ), of any vaccine type
254 is always beneficial as it reduces the size of the susceptible population and can, eventually,
255 achieve herd immunity. Our study showed that the level of IAR always decreased when the
256 capacity multiplier was higher, with the largest impact observed for vaccine- H_iH_f . In particular,
257 when we compared the impact of changing the capacity multiplier from 1.0 to 3.0 for vaccine-
258 H_iH_f , vaccine- M_iM_f , and vaccine- L_iL_f , IAR changed from 72.20% to 59.81% for H_iH_f , from
259 73.89% to 63.13% for M_iM_f , and from 74.77% to 65.01% for L_iL_f , when the difference between
260 the initial and final efficacy was 5% for all the vaccine types and the mutation time was day 25.
261 In addition, if vaccine- H_iH_f could be distributed at a faster rate, the minimum required capacity
262 multiplier (λ) of vaccine- L_iL_f to achieve a lower IAR than vaccine- H_iH_f was even larger. For
263 example, when the mutation time was day 25, the capacity multiplier of vaccine- L_iL_f needed to
264 be at least 1.47 to achieve a lower IAR than vaccine- H_iH_f with the capacity multiplier of 1.0. On
265 the other hand, when the vaccine- H_iH_f 's capacity multiplier was 1.6, the capacity multiplier of
266 vaccine- L_iL_f needed to be at least 2.35. Thus, even though the difference in the capacity
267 multiplier of vaccine- H_iH_f was only 0.60, that of vaccine- L_iL_f was 0.88. However, increasing
268 the capacity multiplier, i.e., the speed of distribution, for vaccine- H_iH_f , which represents mRNA
269 vaccines in our model, may be much more challenging than that for vaccine- L_iL_f , as described
270 above, including economic burden, complications in vaccination programs, and unsophisticated
271 infrastructure. In such cases, it may be more beneficial to allocate resources towards distributing
272 a lower efficacy vaccine at a faster rate as our study shows.

273 Forecasting the daily infection peak and the mutation time also plays an important role when
274 choosing which type of vaccine to distribute. If the mutation time comes after the daily infection
275 peak, a vaccine with a higher initial efficacy always achieves a lower IAR than a vaccine with

276 lower initial efficacy. However, if the mutation time comes before the daily infection peak, the
277 final efficacy level determines which vaccine type achieves a lower IAR under the same capacity
278 multiplier. For example, when we compared vaccine- H_iH_f and vaccine- M_iM_f with a capacity
279 multiplier of 1.0 for each, the daily infection peak occurred on day 22 for both vaccines. Then,
280 the administration of vaccine- M_iM_f , which has an initial efficacy of 75% and final efficacy of
281 70%, resulted in an IAR of 74.06%, whereas the administration of vaccine- H_iL_f , which has an
282 initial efficacy of 95% and final efficacy of 60%, resulted in an IAR of 74.65%. This is because
283 an effective vaccination program achieves the highest reduction in the number of new infections
284 *before* the daily infection peak. Afterwards, even with a higher initial efficacy, a vaccine with a
285 lower final efficacy cannot reduce the size of the susceptible population as much as a vaccine
286 with a lower initial efficacy and a higher final efficacy. Different variants of SARS-CoV-2 that
287 reduces the efficacy of the authorized vaccines have been identified and their potentially higher
288 transmissibility may cause future waves of infections. Thus, careful in vitro and clinical trials
289 against variants are essential before making decisions on vaccine ordering.

290 We acknowledge some limitations of this study. First, our SIR-D model did not capture the
291 full trajectory of SARS-CoV-2. Tindale et al. (2020) reported that the transmission of SARS-
292 CoV-2 starts prior to symptom onset and Cevik et al. (2020) reported that the COVID-19 is most
293 contagious in the first five days of illness, which we did not incorporate into our model [33, 34].
294 In addition, we assumed that the population gains immunity as soon as they receive effective
295 vaccines and that every type of vaccine requires a single dose. In practice, all the authorized
296 vaccines, except Johnson & Johnson's adenovirus-vectored vaccine, require two doses with three
297 to four weeks apart application and it may take several days to gain immunity after vaccination.
298 Moreover, we did not consider any type of non-pharmaceutical interventions. Depending on the

299 number of people who conform to the interventions, such as social distancing and mask
300 mandates, the probability of infectious contacts may vary over time. Lastly, variants may be
301 more transmissible, but we assumed a constant transmission rate in each simulation.

302 Overall, our results suggest that the administration of a vaccine with high efficacy against
303 both the original strain and the variants may not always lead to a low number of cumulative
304 infections if it cannot be distributed as quickly as other vaccine types with lower efficacies.
305 Despite the vast efforts for worldwide vaccination, the vaccine distribution has been an ongoing
306 challenge due to production shortages, economic constraints and the lack of ultra-cold-chain
307 infrastructure, which is critical to distribute some of the early-authorized vaccines. Due to these
308 challenges, especially many low- and middle-income countries have not received a single dose of
309 a vaccine as of mid-February, 2021 [35, 36]. It is critical to distribute available vaccines as
310 quickly as possible and vaccinate more people to reach herd immunity before new variants
311 spread. Our study demonstrates that a vaccine with a relatively lower efficacy can achieve at
312 least as good health outcomes as their higher efficacy counterparts, as long as it can be
313 distributed more quickly. We hope that our study provides guidance to decision makers on the
314 tradeoffs between speed and efficacy, highlighting the critical role of speed of vaccination during
315 a pandemic as variants that decrease efficacy of vaccines emerge.

316 **Acknowledgement**

317 This research has been supported in part by the following Georgia Tech benefactors: William W.
318 George, Andrea Laliberte, Claudia L. and J. Paul Raines, and Richard E. “Rick” and Charlene
319 Zalesky.

Dr. İnci Yildirim reported being a member of the mRNA-1273 Study Group. Dr. Yildirim has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, and Micon. Dr. Pinar Keskinocak received funding to her institution from Merck to conduct non-clinical research. The funders played no role in the study design, data collection, analysis, interpretation, or in writing the manuscript.

320 **References**

- 321 1. World Health Organization. *WHO Coronavirus Disease (COVID-19) Dashboard*. 2020
322 [cited 2021 Apr. 9]; Available from: <https://covid19.who.int>.
- 323 2. Zimmer, C., J. Corum, and S.-L. Wee. *Coronavirus Vaccine Tracker*. New York Times
324 2020 Jan 9 [cited 2021 Apr. 9]; Available from:
325 <https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html>.
- 326 3. Pfizer. *Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved*
327 *Success in First Interim Analysis from Phase-3 Study*. 2020 [cited 2021 Mar. 3];
328 Available from: [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against)
329 [and-biontech-announce-vaccine-candidate-against](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against).
- 330 4. Holm, M.R. and G.A. Poland, *Critical aspects of packaging, storage, preparation, and*
331 *administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal*
332 *efficacy*. *Vaccine*, 2021. **39**(3): p. 457.
- 333 5. Centers for Disease Control and Prevention. *Moderna COVID-19 Vaccine*. 2020 Dec 20,
334 2020 [cited 2021 Apr. 2]; Available from: [https://www.cdc.gov/vaccines/covid-19/info-](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-summary.pdf)
335 [by-product/moderna/downloads/storage-summary.pdf](https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/storage-summary.pdf).
- 336 6. Centers for Disease Control and Prevention. *Information About Johnson & Johnson's*
337 *Janssen COVID-19 Vaccine*. 2021 Mar. 4, 2021 [cited 2021 Mar. 4]; Available from:
338 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html>.
- 339 7. Spalding, R. and C. O'Donnell. *U.S. vaccinations in 2020 fall far short of target of 20*
340 *million people*. 2020 [cited 2021 Mar. 12]; Available from:
341 [https://www.reuters.com/article/us-health-coronavirus-usa-vaccinations/u-s-vaccinations-](https://www.reuters.com/article/us-health-coronavirus-usa-vaccinations/u-s-vaccinations-in-2020-fall-far-short-of-target-of-20-million-people-idUSKBN29512W)
342 [in-2020-fall-far-short-of-target-of-20-million-people-idUSKBN29512W](https://www.reuters.com/article/us-health-coronavirus-usa-vaccinations/u-s-vaccinations-in-2020-fall-far-short-of-target-of-20-million-people-idUSKBN29512W).

- 343 8. Centers for Disease Control and Prevention. *COVID-19 Vaccinations in the United States*.
344 2020 [cited 2021 Mar. 2]; Available from: [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/#vaccinations)
345 [tracker/#vaccinations](https://covid.cdc.gov/covid-data-tracker/#vaccinations).
- 346 9. Lauring, A.S. and E.B. Hodcroft, *Genetic Variants of SARS-CoV-2—What Do They Mean?*
347 *JAMA*, 2021.
- 348 10. Smith-Schoenwalder, C. *CDC: Coronavirus Variant First Found in U.K. Now Dominant*
349 *Strain in U.S.* 2021 [cited 2021 Apr. 9]; Available from:
350 [https://www.usnews.com/news/health-news/articles/2021-04-07/cdc-coronavirus-variant-](https://www.usnews.com/news/health-news/articles/2021-04-07/cdc-coronavirus-variant-first-found-in-uk-now-dominant-strain-in-us)
351 [first-found-in-uk-now-dominant-strain-in-us](https://www.usnews.com/news/health-news/articles/2021-04-07/cdc-coronavirus-variant-first-found-in-uk-now-dominant-strain-in-us).
- 352 11. Liu, Y., et al., *Neutralizing Activity of BNT162b2-Elicited Serum—Preliminary Report*.
353 *New England Journal of Medicine*, 2021.
- 354 12. Rauseo, A.M. and J.A. O’Halloran, *What Are the Clinical Implications of the SARS-CoV-*
355 *2 Variants: 5 Things Every Cardiologist Should Know*. *JACC: Basic to Translational*
356 *Science*, 2021.
- 357 13. Sanders, R.W. and M.D. de Jong, *Pandemic moves and countermoves: vaccines and viral*
358 *variants*. *The Lancet*, 2021.
- 359 14. Mahase, E., *Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60%*
360 *against South African variant*. 2021, British Medical Journal Publishing Group.
- 361 15. Pfizer. *Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns*
362 *Through Up to Six Months Following Second Dose in Updated Topline Analysis of*
363 *Landmark COVID-19 Vaccine Study*. 2021 [cited 2021 Apr. 1]; Available from:
364 [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious)
365 [confirm-high-efficacy-and-no-serious](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious).

- 366 16. Food and Drug Administration. *Fact Sheet for Healthcare Providers Administering*
367 *Vaccine (Vaccine Providers) Emergency Use Authorization (EUA) of the Janssen*
368 *COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19)*. 2021 Feb. 27,
369 2021.
- 370 17. You, C., et al., *Estimation of the time-varying reproduction number of COVID-19*
371 *outbreak in China*. International Journal of Hygiene and Environmental Health, 2020.
372 **228**: p. 113555.
- 373 18. Byrne, A.W., et al., *Inferred duration of infectious period of SARS-CoV-2: rapid scoping*
374 *review and analysis of available evidence for asymptomatic and symptomatic COVID-19*
375 *cases*. BMJ open, 2020. **10**(8): p. e039856.
- 376 19. Centers for Disease Control and Prevention. *COVID-19 Pandemic Planning Scenarios*.
377 2020 [cited 2021 Mar. 3]; Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html)
378 [ncov/hcp/planning-scenarios.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html).
- 379 20. Peeples, L., *Face masks: what the data say*. Nature, 2020. **586**(7828): p. 186-189.
- 380 21. Basu, A., *Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases*
381 *In The United States: Study estimates the COVID-19 infection fatality rate at the US*
382 *county level*. Health Affairs, 2020. **39**(7): p. 1229-1236.
- 383 22. Oran, D.P. and E.J. Topol, *Prevalence of asymptomatic SARS-CoV-2 infection: a*
384 *narrative review*. Annals of internal medicine, 2020. **173**(5): p. 362-367.
- 385 23. Centers for Disease Control and Prevention. *COVID Data Tracker*. 2020 [cited 2021
386 Mar. 2]; Available from: <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>.
- 387 24. Kung, S., et al., *Underestimation of COVID-19 mortality during the pandemic*. ERJ open
388 research, 2021. **7**(1).

- 389 25. Wu, S.L., et al., *Substantial underestimation of SARS-CoV-2 infection in the United*
390 *States*. Nature communications, 2020. **11**(1): p. 1-10.
- 391 26. Noh, J. and G. Danuser, *Estimation of the fraction of COVID-19 infected people in US*
392 *states and countries worldwide*. PloS one, 2021. **16**(2): p. e0246772.
- 393 27. Paltiel, A.D., et al., *Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over*
394 *Efficacy: Study examines how definitions and thresholds of vaccine efficacy, coupled with*
395 *different levels of implementation effectiveness and background epidemic severity,*
396 *translate into outcomes*. Health Affairs, 2021: p. 10.1377/hlthaff.2020.02054.
- 397 28. Paltiel, A.D., A. Zheng, and J.L. Schwartz, *Speed versus efficacy: quantifying potential*
398 *tradeoffs in COVID-19 vaccine deployment*. Annals of internal medicine, 2021.
- 399 29. Bushwick, S. *Why COVID Vaccines Are Taking So Long to Reach You*. 2021 Feb. 11,
400 2021 [cited 2021 Mar. 6]; Available from:
401 [https://www.scientificamerican.com/article/why-covid-vaccines-are-taking-so-long-to-](https://www.scientificamerican.com/article/why-covid-vaccines-are-taking-so-long-to-reach-you/)
402 [reach-you/](https://www.scientificamerican.com/article/why-covid-vaccines-are-taking-so-long-to-reach-you/).
- 403 30. Gabrielson, R., C. Chen, and M. Simon. *How Many Vaccine Shots Go to Waste? Several*
404 *States Aren't Counting*. 2021 [cited 2021 Mar. 6]; Available from:
405 <https://www.propublica.org/article/covid-vaccine-wastage>.
- 406 31. Farmer, B. *Accidentally Trashed, Thawed or Expired: Reports of Covid Vaccine Spoilage*.
407 2021 Mar. 4, 2021 [cited 2021 Mar. 12]; Available from:
408 [https://khn.org/news/article/covid-vaccine-waste-accidentally-thawed-expired-spoilage-](https://khn.org/news/article/covid-vaccine-waste-accidentally-thawed-expired-spoilage-reports-nationwide/)
409 [reports-nationwide/](https://khn.org/news/article/covid-vaccine-waste-accidentally-thawed-expired-spoilage-reports-nationwide/).
- 410 32. Johnson & Johnson. *Johnson & Johnson COVID-19 Vaccine Authorized by U.S. FDA for*
411 *Emergency Use - First Single-Shot Vaccine in Fight Against Global Pandemic*. 2021

412 [cited 2021 Mar. 3]; Available from: [https://www.jnj.com/johnson-johnson-covid-19-](https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic)
413 [vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-](https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic)
414 [against-global-pandemic](https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic).

415 33. Tindale, L.C., et al., *Evidence for transmission of COVID-19 prior to symptom onset*.
416 *Elife*, 2020. **9**: p. e57149.

417 34. Cevik, M., et al., *SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics,*
418 *duration of viral shedding, and infectiousness: a systematic review and meta-analysis*.
419 *The Lancet Microbe*, 2020.

420 35. Dyer, O., *Covid-19: Many poor countries will see almost no vaccine next year, aid*
421 *groups warn*. *BMJ: British Medical Journal (Online)*, 2020. **371**.

422 36. Andrew, S. *More than 130 countries don't have a single Covid-19 vaccine, while 10*
423 *countries have already dispersed 75% of all vaccines, the UN says*. 2021 [cited 2021
424 Mar. 11]; Available from: [https://www.cnn.com/2021/02/18/world/united-nations-130-](https://www.cnn.com/2021/02/18/world/united-nations-130-countries-no-vaccine-trnd/index.html)
425 [countries-no-vaccine-trnd/index.html](https://www.cnn.com/2021/02/18/world/united-nations-130-countries-no-vaccine-trnd/index.html).

426